Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Han X"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 77
Tytuł:
Stereotactic ablative brachytherapy versus percutaneous microwave ablation as salvage treatments for lung oligometastasis from colorectal cancer.
Autorzy:
Li Y; Department of Interventional Medicine and Minimally Invasive Oncology, The Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, 250033, PR of China.; Interventional Oncology Institute, Shandong University, Jinan, PR of China.
Chen Z; Department of Interventional Medicine and Minimally Invasive Oncology, The Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, 250033, PR of China.
Tian S; Department of Interventional Medicine and Minimally Invasive Oncology, The Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, 250033, PR of China.
Han X; Interventional Oncology Institute, Shandong University, Jinan, PR of China.; Department of Radiology, Shandong Provincial Hospital, Jinan, PR of China.
Wang C; Interventional Oncology Institute, Shandong University, Jinan, PR of China.; Department of Radiology, People's Hospital of Jiyang County, Jinan, PR of China.
Wang Y; Department of Interventional Medicine and Minimally Invasive Oncology, The Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, 250033, PR of China.; Interventional Oncology Institute, Shandong University, Jinan, PR of China.
Liu B; Department of Interventional Medicine and Minimally Invasive Oncology, The Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, 250033, PR of China. .; Interventional Oncology Institute, Shandong University, Jinan, PR of China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Apr 16; Vol. 24 (1), pp. 481. Date of Electronic Publication: 2024 Apr 16.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/radiotherapy
Lung Neoplasms*/surgery
Brachytherapy*/adverse effects
Colorectal Neoplasms*/radiotherapy
Colorectal Neoplasms*/surgery
Fistula*/surgery
Liver Neoplasms*/surgery
Catheter Ablation*
Humans ; Retrospective Studies ; Salvage Therapy ; Microwaves/adverse effects ; Treatment Outcome ; Lung/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Single-cell RNA sequencing integrated with bulk RNA sequencing analysis identifies a tumor immune microenvironment-related lncRNA signature in lung adenocarcinoma.
Autorzy:
Ren Y; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Wu R; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Li C; Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Liu L; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shanxi, China.
Li L; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Weng S; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Xu H; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Xing Z; Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China.
Zhang Y; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Wang L; Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Liu Z; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. .; Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. .
Han X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. .
Pokaż więcej
Źródło:
BMC biology [BMC Biol] 2024 Mar 22; Vol. 22 (1), pp. 69. Date of Electronic Publication: 2024 Mar 22.
Typ publikacji:
Journal Article
MeSH Terms:
RNA, Long Noncoding*/genetics
Adenocarcinoma*
Lung Neoplasms*/genetics
Humans ; Sequence Analysis, RNA ; DNA Repair ; Lung ; Tumor Microenvironment/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of malignant pleural effusion.
Autorzy:
Wang K; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Hu X; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Chen Y; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Yi X; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Han X; Department of Geriatrics, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Zhu D; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Zhu B; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Luo H; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
Pokaż więcej
Źródło:
The clinical respiratory journal [Clin Respir J] 2024 Jan; Vol. 18 (1), pp. e13705. Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:
Journal Article
MeSH Terms:
Pleural Effusion, Malignant*/diagnosis
Pleural Effusion, Malignant*/genetics
Pleural Effusion, Malignant*/metabolism
Adenocarcinoma of Lung*/diagnosis
Adenocarcinoma of Lung*/genetics
Lung Neoplasms*/diagnosis
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Pleural Effusion*/diagnosis
Humans ; Carcinoembryonic Antigen/metabolism ; Biomarkers, Tumor/metabolism ; ErbB Receptors/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Microwave ablation for the treatment of peripheral ground-glass nodule-like lung cancer: Long-term results from a multi-center study.
Autorzy:
Yang X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Jin Y; Department of Interventional Therapy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Lin Z; Department of Interventional, Therapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Li X; Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Huang G; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Ni Y; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Li W; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Han X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Meng M; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Chen J; Department of Interventional, Therapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Lin Q; Department of Interventional, Therapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Bie Z; Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Wang C; Department of Thoracic Surgery, Dezhou Second People's Hospital, Dezhou, Shandong, China.
Li Y; Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, China.
Ye X; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China.
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Aug; Vol. 19 (4), pp. 1001-1010.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Lung Neoplasms*/surgery
Pleural Effusion*
Pneumothorax*
Female ; Male ; Humans ; Middle Aged ; Aged ; Microwaves/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Lung cancer-derived exosomal miR-132-3p contributed to interstitial lung disease development.
Autorzy:
Fang S; Respiratory Department, Fuzhou Pulmonary Hospital of Fujian Province, the Teaching Hospital of Fujian Medical University, Fuzhou, 350008, China.
Wang T; Respiratory Department, Fuzhou Pulmonary Hospital of Fujian Province, the Teaching Hospital of Fujian Medical University, Fuzhou, 350008, China.
Weng L; Respiratory Department, Fuzhou Pulmonary Hospital of Fujian Province, the Teaching Hospital of Fujian Medical University, Fuzhou, 350008, China.
Han X; Respiratory Department, Fuzhou Pulmonary Hospital of Fujian Province, the Teaching Hospital of Fujian Medical University, Fuzhou, 350008, China.
Zheng R; Respiratory Department, Fuzhou Pulmonary Hospital of Fujian Province, the Teaching Hospital of Fujian Medical University, Fuzhou, 350008, China.
Zhang H; Respiratory Department, Fuzhou Pulmonary Hospital of Fujian Province, the Teaching Hospital of Fujian Medical University, Fuzhou, 350008, China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2023 Jul 15; Vol. 21 (1), pp. 205. Date of Electronic Publication: 2023 Jul 15.
Typ publikacji:
Journal Article
MeSH Terms:
MicroRNAs*/genetics
MicroRNAs*/metabolism
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Exosomes*/genetics
Humans ; Cell Proliferation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Circular RNA-mediated ceRNA network was identified in human lung adenocarcinoma by high-throughput sequencing.
Autorzy:
Chen Y; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Han X; Second Faculty of Clinical Medicine, Guangdong Medical University, Zhanjiang, China.
Huang X; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Zhou H; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yu H; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Wang L; Key Laboratory of Longevity and Aging-Related Diseases of Chinese Ministry of Education, Center for Translational Medicine & School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Liu Z; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Liu B; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Huang J; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Xiong Y; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Huang J; Department of Thoracic Surgery, Maoming People's Hospital, Maoming, China.
Shao Y; Technical Department, Nanjing Geneseeq Technology Inc., Nanjing, China.
Zhu D; Technical Department, Nanjing Geneseeq Technology Inc., Nanjing, China.
Liang Z; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yang Z; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Su W; Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.; Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Jun; Vol. 14 (16), pp. 1430-1439. Date of Electronic Publication: 2023 May 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
MicroRNAs*/genetics
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/pathology
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; RNA, Circular/genetics ; Biomarkers ; High-Throughput Nucleotide Sequencing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization.
Autorzy:
Chen C; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China.
Dai L; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zheng C; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Li H; Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Li X; Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.; Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Yang M; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Gao R; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Yao J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhang Z; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Han X; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 May 03; Vol. 16 (1), pp. 47. Date of Electronic Publication: 2023 May 03.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/prevention & control
Lung Neoplasms*
Aged ; Humans ; COVID-19 Vaccines/therapeutic use ; Antibody Formation ; Cross-Sectional Studies ; Immunization, Secondary ; SARS-CoV-2 ; Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin G
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
Autorzy:
Hu X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Cui X; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Wang Z; Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Liaoning, China.
Luo Y; Department of Medical Oncology, The First Hospital of China Medical University, Liaoning, China.
Zhong W; Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhao H; Department of Respiratory Medicine, The Second Affiliated Hospital of Anhui Medical University, Anhui, China.
Yao M; Department of Respiratory Medicine, The Second Affiliated Hospital of Anhui Medical University, Anhui, China.
Jiang D; Department of Oncology, Hebei Tumor Hospital, Hebi, China.
Wang M; Department of Oncology, Hebei Tumor Hospital, Hebi, China.
Chen M; Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zheng X; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Ding L; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
Wang Y; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
Yuan X; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
Wu P; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
Hu B; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Han X; Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China. .
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Apr 11; Vol. 23 (1), pp. 331. Date of Electronic Publication: 2023 Apr 11.
Typ publikacji:
Clinical Trial, Phase I; Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Humans ; Proto-Oncogene Proteins c-met/genetics ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Exons
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The ethyl acetate extract of Wenxia Changfu Formula inhibits the carcinogenesis of lung adenocarcinoma by regulating PI3K-AKT signaling pathway.
Autorzy:
Wang L; Department of Medicine, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Rencheng District, Jining City, 272113, Shandong Province, China.
Han X; Emergency Medicine, Jining No. 1 People's Hospital, Jining City, Shandong Province, China.
Li H; Department of Medicine, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Rencheng District, Jining City, 272113, Shandong Province, China.
Lv C; Pharmacy Department, Jining No. 1 People's Hospital, Jining City, Shandong Province, China.
Wang M; Department of Medicine, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Rencheng District, Jining City, 272113, Shandong Province, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Mar 22; Vol. 13 (1), pp. 4715. Date of Electronic Publication: 2023 Mar 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Emodin*/pharmacology
Adenocarcinoma of Lung*/drug therapy
Lung Neoplasms*/pathology
Humans ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; Matrix Metalloproteinase 3/metabolism ; Quercetin/pharmacology ; Signal Transduction ; RNA, Messenger/genetics ; Carcinogenesis ; Molecular Docking Simulation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
MiR-138-5p suppresses the progression of lung cancer by targeting SNIP1.
Autorzy:
Wu J; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.; Department of Laboratory Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
Han X; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.; Department of Laboratory Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
Yang X; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Li Y; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Liang Y; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Sun G; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Wang R; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Wang P; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Xie S; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Feng J; Department of Laboratory Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
Sun H; Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Feb; Vol. 14 (6), pp. 612-623. Date of Electronic Publication: 2023 Jan 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lung Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/pathology
MicroRNAs*/genetics
Humans ; Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic ; RNA-Binding Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PVP with or without microwave ablation for the treatment of painful spinal metastases from NSCLC: a retrospective case-control study.
Autorzy:
Liu Y; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuan H; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Milan S; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang C; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Han X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiao D; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Pokaż więcej
Źródło:
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group [Int J Hyperthermia] 2023; Vol. 40 (1), pp. 2241687.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/surgery
Spinal Neoplasms*/surgery
Spinal Neoplasms*/secondary
Vertebroplasty*/adverse effects
Lung Neoplasms*
Humans ; Retrospective Studies ; Quality of Life ; Case-Control Studies ; Microwaves/therapeutic use ; Pain/etiology ; Treatment Outcome ; Bone Cements
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CT-guided placement of microcoil end in the pleural cavity for video-assisted thoracic surgical resection of ground-glass opacity: a retrospective study.
Autorzy:
An J; Department of Interventional treatment, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, 066000, Qinhuangdao, People's Republic of China.
Dong Y; Department of Interventional treatment, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, 066000, Qinhuangdao, People's Republic of China.
Li Y; Department of Riadiology, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, Qinhuangdao, People's Republic of China.
Han X; Department of Cardiovascular, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, Qinhuangdao, People's Republic of China.
Niu H; Department of Interventional treatment, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, 066000, Qinhuangdao, People's Republic of China. .
Zou Z; Department of Interventional treatment, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, 066000, Qinhuangdao, People's Republic of China.
Wu J; Department of Interventional treatment, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, 066000, Qinhuangdao, People's Republic of China.
Tian Y; Department of Interventional treatment, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, 066000, Qinhuangdao, People's Republic of China.
Chen Z; Department of Interventional treatment, Qinhuangdao Municipal No. 1 Hospital, No. 258 Wenhua Road, Hebei Province, 066000, Qinhuangdao, People's Republic of China.
Pokaż więcej
Źródło:
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2022 Dec 17; Vol. 17 (1), pp. 316. Date of Electronic Publication: 2022 Dec 17.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/surgery
Solitary Pulmonary Nodule*/surgery
Humans ; Retrospective Studies ; Pleural Cavity ; Thoracic Surgery, Video-Assisted/methods ; Tomography, X-Ray Computed/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
IL-17A Promotes the Migration, Invasion and the EMT Process of Lung Cancer Accompanied by NLRP3 Activation.
Autorzy:
Liu W; Department of Rheumatology & Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xin M; Department of Rheumatology & Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Li Q; Department of Rheumatology & Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Sun L; Department of Rheumatology & Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Han X; Department of Rheumatology & Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wang J; Department of Rheumatology & Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2022 Oct 30; Vol. 2022, pp. 7841279. Date of Electronic Publication: 2022 Oct 30 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Epithelial-Mesenchymal Transition*
Lung Neoplasms*/pathology
Humans ; Interleukin-17/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein/genetics ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Cell Movement ; Caspases ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting SPHK1/PBX1 Axis Induced Cell Cycle Arrest in Non-Small Cell Lung Cancer.
Autorzy:
Lin Z; State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, No. 38 Tongyan Road, Jinnan District, Tianjin 300350, China.
Li Y; State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, No. 38 Tongyan Road, Jinnan District, Tianjin 300350, China.
Han X; State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, No. 38 Tongyan Road, Jinnan District, Tianjin 300350, China.
Fu Z; State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, No. 38 Tongyan Road, Jinnan District, Tianjin 300350, China.; Heilongjiang Provincial Key Laboratory for Infection and Immunity, Department of Immunology, Wu Lien-Teh Institute, Heilongjiang Academy of Medical Science, Harbin Medical University, Harbin 150081, China.
Tian Z; Department of Thoracic Surgery, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China.
Li C; State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, No. 38 Tongyan Road, Jinnan District, Tianjin 300350, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Oct 22; Vol. 23 (21). Date of Electronic Publication: 2022 Oct 22.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Cell Cycle Checkpoints/genetics ; Lysophospholipids/metabolism ; Phosphotransferases (Alcohol Group Acceptor) ; Pre-B-Cell Leukemia Transcription Factor 1 ; Proto-Oncogene Proteins c-akt/metabolism ; Sphingosine/metabolism ; Animals
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis.
Autorzy:
Huang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Xie T; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Zhao F; Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Feng Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Zhu H; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Tang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Han X; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Pokaż więcej
Źródło:
Disease markers [Dis Markers] 2022 Oct 21; Vol. 2022, pp. 6512300. Date of Electronic Publication: 2022 Oct 21 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Squamous Cell*/pathology
Humans ; Tumor Microenvironment ; B7-H1 Antigen/genetics ; Prognosis ; Programmed Cell Death 1 Receptor ; Lung/pathology ; Transcription Factors/genetics ; Homeodomain Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Medical Data Analysis of CYP1B1 Gene Polymorphism and Clinical Prognosis of Minimally Invasive Surgery for Lung Cancer.
Autorzy:
Han X; Xingtai People's Hospital, Xingtai, 054001 Hebei, China.
Li D; Xingtai People's Hospital, Xingtai, 054001 Hebei, China.
Zhang S; Xingtai People's Hospital, Xingtai, 054001 Hebei, China.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2022 Sep 24; Vol. 2022, pp. 5217625. Date of Electronic Publication: 2022 Sep 24 (Print Publication: 2022).
Typ publikacji:
Journal Article; Retracted Publication
MeSH Terms:
Leukemia*
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/surgery
Anti-Bacterial Agents/therapeutic use ; Carcinogens ; Cytochrome P-450 CYP1B1/genetics ; Data Analysis ; Humans ; Minimally Invasive Surgical Procedures ; Nucleotides/therapeutic use ; Polymorphism, Genetic ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Study on the Potential Mechanism of miR-22-5p in Non-Small-Cell Lung Cancer.
Autorzy:
Han X; Department of Respiratory and Critical Care Medicine, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Li H; Department of Respiratory and Critical Care Medicine, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Liu S; Department of Respiratory and Critical Care Medicine, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Zhao Z; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Pokaż więcej
Źródło:
Disease markers [Dis Markers] 2022 Sep 06; Vol. 2022, pp. 3750734. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
MicroRNAs*/genetics
MicroRNAs*/metabolism
Cell Movement/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Luciferases/genetics ; Luciferases/metabolism ; RNA, Messenger
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Autorzy:
Han X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Meng M; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Zhang T; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Wang J; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Huang G; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Ni Y; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Li W; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Dai J; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Yang X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Ye X; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong Province, China.
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2022 Sep; Vol. 18 (5), pp. 1440-1443.
Typ publikacji:
Case Reports
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Carcinoma, Non-Small-Cell Lung*/complications
Hypophysitis*/complications
Kidney Neoplasms*/pathology
Lung Neoplasms*/pathology
Aged ; Antibodies, Monoclonal, Humanized ; Glucocorticoids/therapeutic use ; Humans ; Immune Checkpoint Inhibitors ; Male ; Middle Aged ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor ; Steroids/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
Autorzy:
Wang S; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Lou N; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Luo R; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Hao X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Liu Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Wang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Han X; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research & Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1, Shuaifuyuan, Dongcheng District, Beijing, 100730, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2022 May 31; Vol. 20 (1), pp. 248. Date of Electronic Publication: 2022 May 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Chemokine CCL20*/metabolism
Drug Resistance, Neoplasm*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Neovascularization, Pathologic*
Chemokines/metabolism ; Crizotinib/pharmacology ; Humans ; Indoles/pharmacology ; Oncogene Proteins, Fusion ; Protein Kinase Inhibitors/pharmacology ; Pyrazoles/pharmacology ; Quinolines/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A study of microwave ablation for small cell lung cancer.
Autorzy:
Wang J; Department of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Hu L; Department of Radiation Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Yang X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Ye X; Department of Oncology, Shandong Lung Cancer Institute, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Ni Y; Department of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Meng M; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Huang G; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Zhang T; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Li W; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Han X; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Wei Z; Department of Oncology, Shandong Lung Cancer Institute, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Dai J; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Zou Z; Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2022 Apr; Vol. 18 (2), pp. 399-404.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/radiotherapy
Lung Neoplasms*/surgery
Radiofrequency Ablation*/adverse effects
Small Cell Lung Carcinoma*/radiotherapy
Small Cell Lung Carcinoma*/surgery
Humans ; Microwaves/adverse effects ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 77

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies